Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: epicure who wrote (4421)	6/3/1998 7:44:00 PM
From: DD™	Respond to of 7041

This from the Motley Fool has all the makings of a great joke... "Speaking of impotency, biotech firm Zonagen Inc. (Nasdaq: ZONA) dropped $5 1/2 to $31 1/4 after reporting at the Annual Meeting of the American Urological Association that out of patients taking 40 mg and 80 mg doses of its male impotence drug, Vasomax, 51% and 53% (respectively) achieved penetration on 75% of attempts compared with 38% of patients receiving the placebo. While well and good, the unimpressive difference in results between Vasomax and the placebo leaves much to be desired. Side effects were another problem. Some 8% of patients using 40 mg and 18% of patients using 80 mg experienced NASAL CONGESTION."